The present invention relates to liquid formulations of poxvirus, in particular vaccinia virus, stable during storage. Such stable liquid formulations comprise a) a poxvirus, preferably a vaccinia virus, b) a pharmaceutically acceptable buffer, c) a monovalent salt, d) a pharmaceutically acceptable disaccharide or sugar alcohol, and e) a pharmaceutically acceptable chelating agent, wherein the pH of the formulation is comprised between 6.5 and 8.5.La présente invention concerne des formulations liquides de poxvirus, en particulier de virus de la vaccine, stables pendant le stockage. Ces formulations liquides stables comprennent a) un poxvirus, de préférence un virus de la vaccine, b) un tampon pharmaceutiquement acceptable, c) un sel monovalent, d) un disaccharide ou un polyol pharmaceutiquement acceptable et e) un agent chélatant pharmaceutiquement acceptable, le pH de la formulation étant compris entre 6,5 et 8,5.
